Overview

Single/Multiple Dose Bioavailability Trial

Status:
Completed

Trial end date:
2008-03-01

Target enrollment:

Participant gender:

Summary

To determine the pharmacokinetic profile of an extended release tablet of naproxen sodium 660 mg relative to the established commercial Aleve 220 mg tablet following single dose administration and at steady-state following multiple dose administration for 4 days.

Phase:

Phase 1

Details

Lead Sponsor:

Bayer

Treatments:

Naproxen